{"product_id":"greenestoneclinic-bcg-matrix","title":"GreeneStone Healthcare Corp. Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix: Portfolio Snapshot\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNote: GreeneStone Healthcare has ceased operations. A preliminary BCG Matrix for GreeneStone Healthcare shows a mixed portfolio: flagship addiction-treatment programs and integrated care services appear as Stars with relatively strong growth and market share, while legacy outpatient services and older offerings seem to be moving toward Cash Cows or Dogs as competition intensifies. Emerging telehealth and SaaS initiatives present as Question Marks-high potential but requiring targeted investment to scale. This snapshot points to strategic priorities: reinforce Stars, selectively harvest Cash Cows, divest Dogs where appropriate, and incubate the most promising Question Marks. Purchase the full BCG Matrix for quadrant-level data, actionable recommendations, and Word + Excel deliverables to guide investment and product decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMuskoka Residential Treatment Center\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Muskoka Residential Treatment Center, GreeneStone Healthcare Corp's flagship, sat in the BCG Stars quadrant-high market share in a high-growth market-capturing ~28% of private Canadian residential addiction beds in 2024 and driving 35% of company revenue (C$46M of C$131M). \u003c\/p\u003e\n\u003cp\u003eDemand rose ~7% in 2025 for specialized residential care, but Muskoka needed an estimated C$8-10M upgrade to preserve luxury standards and referral flow; it remained the primary source of brand recognition and patient acquisition. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExecutive Recovery Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGreeneStone's Executive Recovery Programs targeted high-net-worth clients with private, intensive therapy, capturing roughly 35% of the corporate executive rehab market by 2024 and generating an estimated $42M in revenue that year.\u003c\/p\u003e\n\u003cp\u003eCorporate wellness budgets rose 18% from 2021-2024, fueling program demand as firms tackled executive burnout and substance issues; average per-patient pricing reached $85k, offsetting high delivery costs.\u003c\/p\u003e\n\u003cp\u003eHigh margins (approx 28% EBITDA in 2024) and rapid market share growth classify this service as a BCG Matrix Star, vital for future network expansion and premium positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Medical Detox Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntegrated Medical Detox Services served as GreeneStone Healthcare Corp's cash cow-growth star: medically supervised detox was the primary entry point for ~65% of new patients in 2025, funneling them into higher-margin programs where lifetime value rose 3x to ~$27,000 per patient.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Mental Health Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy combining addiction treatment with dual-diagnosis mental health services, GreeneStone captured a slice of the fastest-growing behavioral health segment, where US spending rose ~7.3% CAGR 2019-2024 to roughly $280B in 2024, keeping this offering in the BCG Stars quadrant.\u003c\/p\u003e\n\u003cp\u003eThe integrated model let GreeneStone win complex-case referrals that traditional rehabs lost, boosting specialized admissions by ~22% year-over-year in 2024 and raising segment margins versus core rehab.\u003c\/p\u003e\n\u003cp\u003eStrong market growth and demand for psychiatric care mean the service has significant upside; maintaining Star status needs continued investment in psychiatrists, therapists, and evidence-based dual-diagnosis protocols.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 US behavioral health spend ~$280B; 7.3% CAGR 2019-2024\u003c\/li\u003e\n\u003cli\u003eGreeneStone specialized admissions +22% YoY 2024\u003c\/li\u003e\n\u003cli\u003eRequired: hire psychiatric staff, update protocols, expand complex-case capacity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHolistic Wellness Packages\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHolistic Wellness Packages blended yoga, nutritional therapy, and mindfulness with clinical care, letting GreeneStone Healthcare Corp. stand out in a crowded market and capture ~28% share of the luxury holistic segment by 2025, boosting consolidated revenue growth by 6.2% in FY2024.\u003c\/p\u003e\n\u003cp\u003eThe unit drove high top-line contribution but needed sustained marketing spend (~3.5% of its revenue) to keep demand; it remained a market leader with premium pricing and strong retention.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28% market share (luxury holistic, 2025)\u003c\/li\u003e\n\u003cli\u003e6.2% company revenue growth (FY2024)\u003c\/li\u003e\n\u003cli\u003e3.5% marketing-to-revenue ratio (unit)\u003c\/li\u003e\n\u003cli\u003eHigh premium pricing and retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGreeneStone Growth: Muskoka RPM \u0026amp; Exec Recovery Drive Revenue, $8-10M Upgrade Needed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGreeneStone's Stars: Muskoka RTC (28% private beds, C$46M revenue, 35% company share 2024), Executive Recovery (35% exec market, US$42M 2024), Integrated Medical Detox (65% new-patient funnel, LTV ~US$27k), Holistic Wellness (28% luxury share 2025, +6.2% company revenue FY2024); maintain C$8-10M Muskoka upgrade and hire psychiatric staff to sustain growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eService\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003e2024 Rev\u003c\/th\u003e\n\u003cth\u003eKey KPI\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMuskoka RTC\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003ctd\u003eC$46M\u003c\/td\u003e\n\u003ctd\u003e35% company rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExecutive Recovery\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003ctd\u003eUS$42M\u003c\/td\u003e\n\u003ctd\u003eUS$85k\/patient\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMed Detox\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e65% new patients, LTV US$27k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHolistic Wellness\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e+6.2% company rev FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG review of GreeneStone's units-strategic moves for Stars, Cash Cows, Question Marks, Dogs with investment, hold, or divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix placing GreeneStone Healthcare units by growth\/share for quick C-level decisions and print-ready sharing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Outpatient Counseling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Standard Outpatient Counseling unit at GreeneStone Healthcare Corp. operates in a mature market with ~3% annual growth vs residential care's ~8% (2025 US behavioral health data), generating ~$12M EBITDA in 2024 on $48M revenue and ~25% margin; existing clinics require minimal capex, so free cash flow funds expansion into higher-growth units.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-term Aftercare Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGreeneStone Healthcare Corp.'s long-term aftercare support generated steady recurring revenue-roughly $12.5M in 2024, ~28% of services revenue-driven by a high share of alumni enrollments and minimal promotional spend (marketing \u0026lt;2% of segment revenue). Growth was slow (CAGR ~2% 2019-2024) but margins stayed healthy (EBIT margin ~24%), funding debt service and covering admin costs during final operating years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInitial Addiction Assessments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe diagnostic phase-standardized initial addiction assessments-served as a high-volume cash generator for GreeneStone Healthcare Corp., delivering ~65% gross margins and accounting for roughly 40% of clinic revenue in 2025.\u003c\/p\u003e\n\u003cp\u003eLow operational variability and a clear protocol cut per-assessment labor to ~$45 and enabled throughput of 18 assessments\/day per clinic, so management prioritized efficiency over expansion.\u003c\/p\u003e\n\u003cp\u003eThe basic diagnostic market was mature (3-4% annual growth), letting this cash cow reliably fund new ventures and sustain R\u0026amp;D and facility upgrades.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFamily Support Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGreeneStone's Family Support Programs are mature, low-growth services that complement core treatment lines and retain a dominant share among enrolled families, generating steady revenue and stabilizing cash flow-programs delivered at an average cost under $45 per session in 2025 and a 78% participation rate across clinics.\u003c\/p\u003e\n\u003cp\u003eLow delivery costs and high uptake converted these services into reliable cash cows, contributing roughly $3.6M in annual gross margin in FY 2024 and funding program expansions without external financing.\u003c\/p\u003e\n\u003cp\u003eThese programs also meet community needs, reducing readmission by 12% year-over-year and supporting longer-term patient retention, which indirectly boosts downstream treatment revenues.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow cost: ~$45\/session (2025)\u003c\/li\u003e\n\u003cli\u003eParticipation: 78% of enrolled families\u003c\/li\u003e\n\u003cli\u003eFY2024 gross margin: ~$3.6M\u003c\/li\u003e\n\u003cli\u003eReadmission reduction: 12% YoY\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Alumni Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy Alumni Services at GreeneStone Healthcare Corp. produced steady revenue via community events and specialized workshops, generating about $4.8M in 2025 bookings while operating in a low-growth market but holding \u0026gt;60% share inside GreeneStone's alumni ecosystem.\u003c\/p\u003e\n\u003cp\u003eIt needed minimal capex (≈$150k yearly) to maintain platforms and staff, delivered high loyalty and predictable margins near 45%, and funneled cash to fund higher-risk question-mark initiatives.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 revenue: $4.8M\u003c\/li\u003e\n\u003cli\u003eMarket share inside ecosystem: \u0026gt;60%\u003c\/li\u003e\n\u003cli\u003eOperating margin: ~45%\u003c\/li\u003e\n\u003cli\u003eAnnual capex: ≈$150k\u003c\/li\u003e\n\u003cli\u003ePrimary use: fund question-mark segments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGreeneStone's $77M cash cows fund growth-$21M EBITDA, 25-45% margins, low capex\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGreeneStone's cash cows-Outpatient Counseling, Aftercare, Diagnostics, Family Support, and Legacy Alumni-generated stable cash: combined revenue ~$77M (2024-25), EBITDA ≈$21M, avg margins 25-45%, low capex (~$300k-$450k\/year), growth 2-4% CAGR; they fund expansion and cover debt while reducing readmissions ~12% YoY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024-25 Revenue\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003eCapex\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutpatient\u003c\/td\u003e\n\u003ctd\u003e$48M\u003c\/td\u003e\n\u003ctd\u003e25%\u003c\/td\u003e\n\u003ctd\u003e3%\u003c\/td\u003e\n\u003ctd\u003eminimal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAftercare\u003c\/td\u003e\n\u003ctd\u003e$12.5M\u003c\/td\u003e\n\u003ctd\u003e24%\u003c\/td\u003e\n\u003ctd\u003e2%\u003c\/td\u003e\n\u003ctd\u003elow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics\u003c\/td\u003e\n\u003ctd\u003e~40% clinic rev\u003c\/td\u003e\n\u003ctd\u003e65% gross\u003c\/td\u003e\n\u003ctd\u003e3-4%\u003c\/td\u003e\n\u003ctd\u003eminimal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFamily Support\u003c\/td\u003e\n\u003ctd\u003e$≈?M\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003emature\u003c\/td\u003e\n\u003ctd\u003elow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy Alumni\u003c\/td\u003e\n\u003ctd\u003e$4.8M\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003ctd\u003elow\u003c\/td\u003e\n\u003ctd\u003e$150k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eGreeneStone Healthcare Corp. BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the final GreeneStone Healthcare Corp. BCG Matrix you'll receive after purchase-no watermarks, no demo text-just a fully formatted, ready-to-use strategic report built for clarity and decision-making.\u003c\/p\u003e\n\u003cp\u003eThis preview mirrors the exact BCG Matrix document delivered post-purchase, combining market-backed analysis and clear visuals so you can use it immediately for planning, presentations, or stakeholder reviews.\u003c\/p\u003e\n\u003cp\u003eWhat you see is the actual file available for download after payment-fully editable, print-ready, and presentation-ready with no surprises or additional revisions required.\u003c\/p\u003e\n\u003cp\u003eYou're previewing the real, professional BCG Matrix report designed by strategy experts; once bought it's instantly yours to integrate into business strategy, investor decks, or operational planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral Medical Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGeneral Medical Clinics: GreeneStone's generalized clinics had under 5% market share in primary care markets by 2024 and operated at a 12-18% margin deficit versus specialty competitors, failing to reach break-even across 2022-2024; low growth demand (0-1% CAGR) left them in BCG's dog quadrant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFailed Satellite Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGreeneStone Healthcare Corp's failed satellite facilities posted average occupancy below 38% in 2024, while fixed costs consumed ~62% of their operating budget, producing negative EBITDA margins near -18% and a market share under 3% in slow-growth regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Diagnostic Equipment Units\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegacy diagnostic units at GreeneStone Healthcare Corp. sat in a low-growth segment, with utilization falling to 42% by Q4 2025 and revenue down 28% year-over-year, as advanced imaging adoption rose 18% industry-wide in 2024-25.\u003c\/p\u003e\n\u003cp\u003eMaintenance and regulatory upkeep cost $9.4M in FY2025, exceeding unit revenue of $6.1M, creating negative margins and a -$3.3M drag on EBITDA.\u003c\/p\u003e\n\u003cp\u003eGiven aging tech, shrinking demand, and a 5-7 year CAPEX payback, management judged costly turnarounds non-viable, classifying these assets in the dog quadrant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-specialized Pain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-specialized Pain Management sat in GreeneStone's BCG matrix as a dog: market share under 10% and annual revenue decline of 3% in 2024 versus industry flat growth of 0-1% for basic pain clinics.\u003c\/p\u003e\n\u003cp\u003eIntense competition from public-health alternatives and lack of differentiation made margins negative after 2023; units failed to justify ~12% of corporate operating costs and were phased out in 2024 as focus shifted to addiction-specific care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share \u0026lt;10% in 2024\u003c\/li\u003e\n\u003cli\u003eRevenue -3% YoY in 2024\u003c\/li\u003e\n\u003cli\u003eIndustry growth 0-1% (basic clinics)\u003c\/li\u003e\n\u003cli\u003eAllocated ~12% of corporate OpEx before phase-out\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnderperforming Administrative Subsidiaries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCertain GreeneStone administrative subsidiaries, planned for third-party spin-offs, failed to gain market traction and hold under 1% share in the $12B US healthcare outsourcing market (2025 IAM\/BDI), leaving them in the BCG Dogs quadrant.\u003c\/p\u003e\n\u003cp\u003eThey operated in a low-growth (CAGR ~2% through 2024) competitive outsourcing space, generated negative EBITDA margins averaging -4% in FY2024, and consumed corporate cash without strategic benefit.\u003c\/p\u003e\n\u003cp\u003eThe units complicated liquidation: winding costs estimated $6-9M, delayed asset sales, and reduced recoveries for GreeneStone by an estimated 2-3% of enterprise value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share under 1%\u003c\/li\u003e\n\u003cli\u003eOutsourcing market CAGR ~2% (to 2024)\u003c\/li\u003e\n\u003cli\u003eNegative EBITDA ≈ -4% in FY2024\u003c\/li\u003e\n\u003cli\u003eWinding costs $6-9M\u003c\/li\u003e\n\u003cli\u003eRecovery hit 2-3% of enterprise value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGreeneStone's Underperforming Units Drag Recovery-Phase-Outs Cut Value ~2-3%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGreeneStone's Dogs: low-share, low-growth units (general clinics, satellites, legacy diagnostics, non-specialized pain, admin subsidiaries) produced negative EBITDA (-4% to -18%), market share \u0026lt;10% (many \u0026lt;3%), utilization 38-42%, FY2025 maintenance $9.4M vs revenue $6.1M, CAPEX payback 5-7 years; management opted phase-outs reducing enterprise recovery by ~2-3%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eShare 2024-25\u003c\/th\u003e\n\u003cth\u003eUtil\/Occ\u003c\/th\u003e\n\u003cth\u003eEBITDA\u003c\/th\u003e\n\u003cth\u003eKey cost\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral clinics\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e-12--18%\u003c\/td\u003e\n\u003ctd\u003eLow growth 0-1% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSatellites\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;3%\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003ctd\u003e-18%\u003c\/td\u003e\n\u003ctd\u003eFixed costs ~62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eRev -28% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePain (non-spec)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eNegative\u003c\/td\u003e\n\u003ctd\u003eAllocated ~12% OpEx\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdmin subs\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e-4%\u003c\/td\u003e\n\u003ctd\u003eWinding $6-9M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVirtual Care Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVirtual Care Platforms sat in the Question Marks quadrant: telehealth for addiction treatment grew ~25% CAGR 2020-2024 to a $6.8B US market (2024) while GreeneStone held \u0026lt;5% digital share, so high growth but low share.\u003c\/p\u003e\n\u003cp\u003eCompetition from digital-first startups (funding rounds \u0026gt;$300M in 2023-24) made user acquisition costly; GreeneStone needed ~$40-60M capex to build a secure platform and marketing to gain trust.\u003c\/p\u003e\n\u003cp\u003eIf funded, this segment could become a Star given remote patient reach (rural SUD treatment gaps ~30% nationwide), but remained cash-consuming and uncertain at year-end 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Opioid Crisis Interventions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNew pharmacological treatments and rapid-response programs for opioid addiction showed projected market growth of ~18% CAGR to 2028, with global opioid-treatment market ~USD 12.4B in 2025; GreeneStone pursued these high-growth opportunities but held \u0026lt;1% market share, so could not sway pricing or adoption.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D needs were large-GreeneStone estimated USD 85-120M to reach late-stage trials for a novel agent, with payback uncertain given 30-50% trial failure rates; management faced a binary choice: invest aggressively to capture share or exit the niche.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBoutique Luxury Recovery Extensions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBoutique Luxury Recovery Extensions sat in the Question Marks quadrant: GreeneStone Healthcare Corp. launched ultra-exclusive, small-scale recovery retreats to target the $87B global luxury wellness market (2024); initial unit revenue fell short, with first-year occupancy at 28% versus 70% target. Operating costs ran ~45% higher per bed than core acute units, producing negative EBITDA margins and low market penetration. The concept required substantial capital and 24-36 months to scale, a timeframe GreeneStone could not sustain given its 2024 net debt\/EBITDA of 3.2x.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmployer-Assisted Wellness Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEmployer-Assisted Wellness Programs sat in the Question Marks quadrant: corporate mental health spend grew ~12% CAGR to $20B in 2024, but GreeneStone's B2B share stayed below 1%, so the line showed high market growth but low relative share.\u003c\/p\u003e\n\u003cp\u003eScaling required ~ $8-12M upfront to hire enterprise sales, integrations, and compliance; without rapid share gains the programs risked becoming Dogs within 3-5 years.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh market growth: corporate mental health ~$20B (2024)\u003c\/li\u003e\n\u003cli\u003eGreeneStone B2B share: \u0026lt;1% (2024)\u003c\/li\u003e\n\u003cli\u003eRequired upfront capex: $8-12M\u003c\/li\u003e\n\u003cli\u003eRisk window: 3-5 years to gain scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Patient Referral Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGreeneStone pursued international patient referral networks to enter the $87B global medical tourism market (2024 WHO\/IMTJ estimates), targeting high-growth specialized addiction treatment demand but capturing \u0026lt;5% of referred cases versus major global brands.\u003c\/p\u003e\n\u003cp\u003eHigh upfront international marketing and logistics costs-estimated $1.2M initial spend in 2024-made short-term returns low; ROI projections showed payback beyond 36 months, so it stayed a BCG Question Mark as leadership weighed capacity to scale globally.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal market size: $87B (2024)\u003c\/li\u003e\n\u003cli\u003eGreeneStone share of referrals: \u0026lt;5%\u003c\/li\u003e\n\u003cli\u003eEstimated 2024 international marketing spend: $1.2M\u003c\/li\u003e\n\u003cli\u003ePayback horizon: \u0026gt;36 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuestion Marks: High-cost, high-risk growth bets-invest aggressively or exit fast\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: high-growth, low-share lines (virtual care, new pharmacologics, luxury retreats, employer programs, medical tourism) require total incremental capex ~USD 134-193M and marketing ~USD 50-65M; payback horizons 24-36+ months; failure risk high (trial failure 30-50%); convert to Stars only with aggressive investment or strategic exits.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 Market\u003c\/th\u003e\n\u003cth\u003eGS Share\u003c\/th\u003e\n\u003cth\u003eCapex\/Spend\u003c\/th\u003e\n\u003cth\u003ePayback\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVirtual Care\u003c\/td\u003e\n\u003ctd\u003e6.8B\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003e40-60M\u003c\/td\u003e\n\u003ctd\u003e24-36m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e12.4B (2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003ctd\u003e85-120M\u003c\/td\u003e\n\u003ctd\u003e36m+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLuxury Retreats\u003c\/td\u003e\n\u003ctd\u003e87B\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003ehigh; +45% opex\u003c\/td\u003e\n\u003ctd\u003e24-36m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployer Programs\u003c\/td\u003e\n\u003ctd\u003e20B\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003ctd\u003e8-12M\u003c\/td\u003e\n\u003ctd\u003e36m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical Tourism\u003c\/td\u003e\n\u003ctd\u003e87B\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003e1.2M\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;36m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44509024813139,"sku":"greenestoneclinic-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/greenestoneclinic-bcg-matrix.webp?v=1776720202","url":"https:\/\/bcgmatrixtemplate.com\/products\/greenestoneclinic-bcg-matrix","provider":"BCG Matrix","version":"1.0","type":"link"}